INMB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
INmune Bio Inc (INMB) is not a strong buy for a beginner investor with a long-term strategy at this moment. The stock lacks clear positive momentum or strong catalysts, and its financial performance is weak. Additionally, there are no significant trading signals or recent news to support a buy decision.
The technical indicators are neutral to bearish. The MACD is slightly positive but contracting, RSI is neutral at 48.465, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 1.319, with key support at 1.201 and resistance at 1.438.
Lucid Capital recently upgraded the stock to Buy with a price target increase from $2 to $9, citing the potential of the company's CORDStrom therapy and expanded pipeline value drivers.
The stock is down 1.50% in pre-market trading, and there are no significant hedge fund, insider, or congress trading activities. The financial performance is weak, with declining net income (-46.48% YoY) and EPS (-60.00% YoY).
In 2025/Q3, the company's revenue remained at $0 with no growth. Net income dropped significantly to -$6.47M (-46.48% YoY), and EPS declined to -0.24 (-60.00% YoY). Gross margin remains at 100%, but this is not meaningful given the lack of revenue.
Lucid Capital upgraded the stock to Buy from Neutral with a price target increase to $9 (from $2), citing the company's CORDStrom therapy and expanded pipeline potential.
